SCHEMBL5374261

SCHEMBL5374261

O=C(O)NCCc1cccc(-c2ccc(O)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 2/20 0.49
PLAAT5 Q96KN8 2/20 0.49
PLAAT2 Q9NWW9 2/20 0.49
PLAAT4 Q9UL19 2/20 0.49
MMP3 P08254 1/20 0.49
TRPV1 Q8NER1 1/20 0.47
HIF1A Q16665 2/20 0.47
MEN1 O00255 1/20 0.47
ESR1 P03372 1/20 0.47
KMT2A Q03164 1/20 0.47
ACMSD Q8TDX5 1/20 0.47
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
SPR P35270 1/20 0.46
AOC3 Q16853 2/20 0.46
KDM4E B2RXH2 1/20 0.45
F13A1 P00488 1/20 0.45
FAAH O00519 1/20 0.45
GPR84 Q9NQS5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278183 0.85 HCAR2 (0.54) PLAAT3PLAAT5PLAAT2PLAAT4MEN1
SCHEMBL2454247 0.84 AOC3 (0.59) MMP3MEN1ESR1KMT2AAOC3
SCHEMBL21049906 0.84 AKR1C3 (0.53) PLAAT3PLAAT5PLAAT2PLAAT4MEN1
SCHEMBL3340166 0.84 AOC3 (0.51) PLAAT3PLAAT5PLAAT2PLAAT4HIF1A
SCHEMBL3948564 0.84 PLAAT3 (0.50) PLAAT3PLAAT5PLAAT2PLAAT4HIF1A
SCHEMBL15111915 0.83 RAB9A (0.57) HIF1A
SCHEMBL2749289 0.82 SPR (0.63) PLAAT3PLAAT5PLAAT2PLAAT4TRPV1
SCHEMBL3345753 0.79 FAAH (0.53) AOC3FAAH
SCHEMBL1728418 0.79 CNR1 (0.59) PLAAT5PLAAT4MMP3HIF1AMEN1
SCHEMBL1437502 0.78 KDM4E (0.69) PLAAT3PLAAT5PLAAT2PLAAT4ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307078-B2 Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-11 US disclosed
US-20070093487-A1 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-04-26 US disclosed
US-7125869-B2 Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-24 US disclosed
US-20060009484-A1 Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-12 US disclosed
EP-1572629-A1 COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2005-09-14 EP disclosed
WO-2004052840-A1 COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093487-A1 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics MITF, AHR, PAH PLAAT3 723/4885PLAAT5 812/4885PLAAT2 381/4885
US-20060009484-A1 Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA PLAAT3 479/4885PLAAT5 825/4885PLAAT2 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.